Navigation Links
Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
Date:10/2/2009

LACHEN, Switzerland, Oct. 2 /PRNewswire/ -- Through June 2009, Octapharma AG realized a record turnover of 536 M euro, compared to 422 M euro as of year-to-date June 2008, an increase of 27%.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091002/NY86257)

The cost of sales increased proportionally more than the turnover, decreasing gross margin from 46.4% to 43.3%, primarily due to increased plasma costs.

Due to increased efficacy in other areas, Octapharma reached a satisfactory level in its operating income through June 2009 (earnings before interest and taxes) of 173 M euro (32.3% margin), compared with 141 M euro (33.4% margin) in the same period of 2008.

Plasma Protein Industry's Outlook for the Second Half 2009 and 2010

In the area of plasma collection, the fact that plasma collection centers are closing on Saturdays and that the remaining independent plasma suppliers offer discounts confirms that there is an oversupply.

Declining prices in government and hospital tenders worldwide also point in this direction.

In spite of a continuous growth of 5% - 6% in the IVIG market we therefore expect monthly sales to stay at the present level with higher quantities the remaining part of 2009. 2010 will remain flat compared to 2009, again with higher unit sales.

A high pressure in many countries on the reimbursement structure will further contribute to the negative trend. However, the patients can on this basis experience a more stable supply of products with fewer interruptions. Octapharma intends to overcome the present trend by the launch of new products.

Octapharma AG

Headquartered in Lachen, Switzerland, Octapharma is the third largest plasma products manufacturer in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration, providing the highest level of production flexibility and minimizing product shortages. For more information, please visit www.octapharma.com.

Forward-looking statements

This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.

SOURCE Octapharma AG


'/>"/>
SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
2. Pillar Capital Announces Acquisition of Medico Labs Assets
3. Cyberonics Announces Epilepsy Technology Collaborations
4. Bionovo Announces Pricing of Securities Offering
5. Winner Medical Announces Two-for-One Reverse Stock Split
6. DST Systems, Inc. Announces Exchange Transaction Involving 4.125% Series A Convertible Senior Debentures
7. Healthcare Realty Trust Announces New $550 Million Unsecured Revolving Credit Facility
8. Lumetra Announces Sale of Subsidiary IntegriGuard
9. UCSF Announces Expanded BreastCancerTrials.org Website
10. DSS Research Announces Senior Health Risk Assessment (SrHRA)(TM)
11. US Farms, Inc. Announces Distribution Partnership With Natures Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... an inspirational story for those shackled by the chains of a broken life. “God ... and a woman of great faith and wisdom. She is a great motivational speaker. ... and raised in Vero Beach, Florida and has dedicated her life and ministry to letting ...
(Date:8/15/2017)... ... 2017 , ... The first study to report that overall survival was extended ... the team’s findings now published online ahead of print in the Journal of Clinical ... Marrow Transplant Program at Roswell Park Cancer Institute, was principal investigator for one of ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Progressive Dental, a ... a spot on the 2017 Fast 50 list of Fastest Growing Companies in Tampa ... seven county area who has shown three consecutive years of growth. For this year’s ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy ... patient’s periodontal disease . This information can be used to develop patient-specific ... , The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by ...
(Date:8/15/2017)... ... August 15, 2017 , ... Rejuvenate ... of services. FDA-cleared CoolSculpting is the world’s most popular non-invasive fat reduction treatment, ... CoolSculpting can reduce fat cells in almost any area of the body, including ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology: